袁小威;杜宁;吴建珩;

• 1:郑州大学第五附属医院

摘要(Abstract)：

目的探究缺血型烟雾病患者行血运重建术后再发脑梗死的危险因素。方法以2016-03—2018-12于郑州大学第五附属医院行血运重建术的92例缺血型烟雾病患者为研究对象，针对其临床资料和随访资料进行回顾性分析，采用多因素Logistic回归方法分析缺血型烟雾病患者血运重建术后再发脑梗死的危险因素。结果 92例患者至随访结束时均存活，其中12例术后至随访结束再发脑梗死，其余80例术后无脑梗死。多因素Logistic回归分析表明术前Suzuki分期（OR=75.102,95%CI3.781～1 491.721,P=0.005）、mRS评分（OR=15.712,95%CI 1.975～124.975,P=0.009）可影响术后再发脑梗死的概率。结论 烟雾病应早期手术，及时在Suzuki分期的早期和mRS评分较低的阶段进行手术，术后再发脑梗死的风险相对较小，手术效果更好。

关键词(KeyWords)： 烟雾病;再发脑梗死;血运重建术;危险因素;预后;Suzuki分期;mRS评分

Abstract:

Keywords:

基金项目(Foundation): 河南省医学科技攻关计划（联合共建）项目（编号：LHGJ20190417）

作者(Authors): 袁小威;杜宁;吴建珩;

参考文献(References)：

• [1]WIEDMANN M K H,DAVIDOFF C,LO PRESTI A,et al.Treatment of ruptured aneurysms of the choroidal collateral system in moyamoya disease:a systematic review and data analysis[J].J Neurosurg,2021,136(3):637-646.DOI:10.3171/2021.1.JNS203936.
• [2]孙玮良，赵黎明，梁浩，等.烟雾病的临床特征及外科治疗的流行病学分析[J].中国实用神经疾病杂志，2020,23(6):485-490.DOI:10.12083/SYSJ.2020.06.025.
• [3]CANAVERO I,VETRANO I G,ZEDDE M,et al.Clinical Management of Moyamoya Patients[J].J Clin Med,2021,10(16):3628.DOI:10.3390/jcm10163628.
• [4]WEI W,CHEN X,YU J,et al.Risk factors for postoperative stroke in adults patients with moyamoya disease:a systematic review with meta-analysis[J].BMC Neurol,2019,19(1):98.DOI:10.1186/s12883-019-1327-1.
• [5]LAI P M R,PATEL N J,FRERICHS K U,et al.Direct vs Indirect Revascularization in a North American Cohort of Moyamoya Disease[J].Neurosurgery,2021,89(2):315-322.DOI:10.1093/neuros/nyab156.
• [6]HARA S,NARIAI T,INAJI M,et al.Imaging Pattern and the Mechanisms of Postoperative Infarction After Indirect Revascularization in Patients with Moyamoya Disease[J].World Neurosurg,2021,155:e510-e521.DOI:10.1016/j.wneu.2021.08.098.
• [7]烟雾病和烟雾综合征诊断与治疗中国专家共识编写组，国家卫生计生委脑卒中防治专家委员会缺血性卒中外科专业委员会.烟雾病和烟雾综合征诊断与治疗中国专家共识（2017)[J].中华神经外科杂志，2017,33(6):541-547.DOI:10.3760/cma.j.issn.1001-2346.2017.06.001.
• [8]ZHANG K,REN W,SUN Y X,et al.Angiographic Characteristics of Cerebral Perfusion and Hemodynamics of the Bridging Artery After Surgical Treatment of Unilateral Moyamoya Disease[J].Front Neurosci,2022,16:922482.DOI:10.3389/fnins.2022.922482.
• [9]SUDHIR B J,KARTHIKAYAN A,AMJAD J M,et al.Strategic tunnelling of superficial temporal artery during bypass surgery for moyamoya disease[J].Acta Neurochir(Wien),2022,164(4):1021-1025.DOI:10.1007/s00701-021-05084-8.
• [10]梁浩，赵黎明，孙玉学，等.联合脑血运重建治疗老年烟雾病患者的临床研究[J].中国实用神经疾病杂志，2021,24(5):388-395.DOI:10.12083/SYSJ.2021.15.004.
• [11]EGUCHI S,AIHARA Y,CHIBA K,et al.Do Direct Bypasses Really Resolve Capillary Vessels in Moyamoya Disease?Delayed Hemorrhage Potentially Relevant to Direct Bypasses:APathological Investigation[J].Pediatr Neurosurg,2020,55(4):203-209.DOI:10.1159/000509125.
• [12]李魁元，李红伟，杨波，等.烟雾病的后循环分级与手术疗效及灌注的相关性[J].中国实用神经疾病杂志，2022,25(3):265-269.DOI:10.12083/SYSJ.220155.
• [13]QIAN Y,HUANG B,HU Z,et al.Analysis of Factors Related to Cerebral Infarction after Direct Bypass Surgery in Adults with Moyamoya Disease[J].Cerebrovasc Dis,2020,49(1):55-61.DOI:10.1159/000504743.
• [14]ARAKI Y,YOKOYAMA K,UDA K,et al.Ipsilateral late stroke after revascularization surgery for patients with Moyamoya disease.Acta Neurochir (Wien),2021,163(5):1493-1502.DOI:10.1007/s00701-021-04773-8.
• [15]梁浩，赵黎明，高涛，等.联合脑血管重建术治疗成人烟雾病术后相关并发症的影响因素分析[J].中华神经外科杂志，2021,37(3):245-249.DOI:10.3760/cma.j.cn112050-20201118-00579.
• [16]ARAKI Y,UDA K,YOKOYAMA K,et al.Risk Factors for Cerebral Infarction Early After Revascularization in Children Younger than 5 Years with Moyamoya Disease[J].World Neurosurg,2022,160:e220-e226.DOI:10.1016/j.wneu.2021.12.115.
• [17]HAYASHI T,KIMIWADA T,KARIBE H,et al.Preoperative Risks of Cerebral Infarction in Pediatric Moyamoya Disease[J].Stroke,2021,52(7):2302-2310.DOI:10.1161/STROKEAHA.120.032699.
• [18]MURAOKA S,ARAKI Y,KONDO G,et al.Postoperative Cerebral Infarction Risk Factors and Postoperative Management of Pediatric Patients with Moyamoya Disease[J].World Neurosurg,2018,113:e190-e199.DOI:10.1016/j.wneu.2018.01.212.
• [19]BAO X Y,DUAN L,LI D S,et al.Clinical features,surgical treatment and long-term outcome in adult patients with Moyamoya disease in China[J].Cerebrovasc Dis,2012,34(4):305-313.DOI:10.1159/000343225.
• [20]KAZUMATA K,ITO M,TOKAIRIN K,et al.The frequency of postoperative stroke in moyamoya disease following combined revascularization:a single-university series and systematic review[J].J Neurosurg,2014,121(2):432-440.DOI:10.3171/2014.1.JNS13946.
• [21]FUJIMURA M,MUGIKURA S,KANETA T,et al.Incidence and risk factors for symptomatic cerebral hyperperfusion after superficial temporal artery-middle cerebral artery anastomosis in patients with moyamoya disease[J].Surg Neurol,2009,71(4):442-447.DOI:10.1016/j.surneu.2008.02.031.
• [22]YU Z,BAI X,ZHANG Y,et al.Baseline Hemodynamic Impairment and Revascularization Outcome in Newly Diagnosed Adult Moyamoya Disease Determined by Pseudocontinuous Arterial Spin Labeling[J].World Neurosurg,2022:S1878-8750(22)00869-5.DOI:10.1016/j.wneu.2022.06.084.
• [23]DENG X,GE P,WANG R,et al.Risk factors for postoperative ischemic complications in pediatric moyamoya disease[J].BMCNeurol,2021,21(1):229.DOI:10.1186/s12883-021-02283-9.
• [24]ZHAO M,DENG X,ZHANG D,et al.Risk factors for and outcomes of postoperative complications in adult patients with moyamoya disease[J].J Neurosurg,2018:1-12.DOI:10.3171/2017.10.JNS171749.
• [25]MA Y,ZHAO M,DENG X,et al.Comparison of clinical outcomes and characteristics between patients with and without hypertension in moyamoya disease[J].J Clin Neurosci,2020,75:163-167.DOI:10.1016/j.jocn.2019.12.016.
• [26]NOH H J,KIM S J,KIM J S,et al.Long term outcome and predictors of ischemic stroke recurrence in adult moyamoya disease[J].J Neurol Sci,2015,359(1/2):381-388.DOI:10.1016/j.jns.2015.11.018.
• [27]ELMAHDI M,FADALLA T,SULIMAN M,et al.Moyamoya syndrome and stroke among pediatric sickle cell disease patients in Sudan:A cross-sectional study[J].Ann Med Surg(Lond),2022,78:103815.DOI:10.1016/j.amsu.2022.103815.
• [28]XU S,WEI W,ZHANG F,et al.Transcriptomic Profiling of Intracranial Arteries in Adult Patients With Moyamoya Disease Reveals Novel Insights Into Its Pathogenesis[J].Front Mol Neurosci,2022,15:881954.DOI:10.3389/fnmol.2022.881954.
• [29]HARRIS M K,GRAHAM R T,CAPPELLANO A M,et al.Multiinstitutional analysis of central nervous system germ cell tumors in patients with Down syndrome[J].Pediatr Blood Cancer,2022:e29830.DOI:10.1002/pbc.29830.
• [30]XUE Y,ZHANG Q,WANG L J,et al.Application of Induced Pluripotent Stem Cells in Moyamoya Disease:Progress and Promises[J].Curr Stem Cell Res Ther,2022 Jun 7.DOI:10.2174/1574888X17666220607121027.
• [31]YEARLEY A G,BERNSTOCK J D,KAPPEL A D,et al.“Recycling”a failed superficial temporal artery indirect bypass into a double barrel direct bypass in moyamoya disease[J].JStroke Cerebrovasc Dis,2022,31(8):106581.DOI:10.1016/j.jstrokecerebrovasdis.2022.106581.
• [32]LIAO Y,XU F,XU B.How I do it:superficial temporal artery to middle cerebral artery bypass for moyamoya disease[J].Acta Neurochir (Wien),2022,164(7):1855-1859.DOI:10.1007/s00701-022-05255-1.
• [33]MA J,FU X,ZHOU S,et al.Study on the serum level of Co Q10Bin patients with Moyamoya disease and its mechanism of affecting disease progression[J].Arq Neuropsiquiatr,2022,80(5):469-474.DOI:10.1590/0004-282X-ANP-2021-0002.
• [34]SHIRO T,YAMAMOTO S,HAMADA S,et al.Negative Remodeling of Carotid Canal during Spontaneous Disease Progression in Moyamoya Disease[J].World Neurosurg,2022,161:e268-e273.DOI:10.1016/j.wneu.2022.01.111.
• [35]FUJIMURA M.Moyamoya Disease-Standards and Advances in Revascularization Procedure and Peri-operative Management[J].Adv Tech Stand Neurosurg,2022,44:175-186.DOI:10.1007/978-3-030-87649-4_9.
• [36]GAO T,ZOU C,LI J,et al.Identification of moyamoya disease based on cerebral oxygen saturation signals using machine learning methods[J].J Biophotonics,2022,15(7):e202100388.DOI:10.1002/jbio.202100388.
• [37]ZHANG X,SU J,YU J,et al.Application of intraoperative electrocorticography in bypass surgery for adult moyamoya disease:a preliminary study[J].Front Biosci(Landmark Ed),2022,27(1):26.DOI:10.31083/j.fbl2701026.
• [38]KIM H J,CHOI S H,KWON H,et al.Spinal Versus General Anesthesia for Cesarean Delivery in Pregnant Women With Moyamoya Disease:A Retrospective Observational Study[J].Anesth Analg,2022 Jan 27.DOI:10.1213/ANE.0000000000005919.
• [39]MA Y,LU X,ZENG G,et al.Vascular Architecture Characters and Changes of Pediatric Moyamoya Disease after Combined Bypass Surgery[J].Neuropediatrics,2022,53(3):188-194.DOI:10.1055/a-1753-2634.
• [40]WU H,XIA C,LI R,et al.Correlation Between Apelin and Collateral Circulation in Patients with Middle Cerebral Artery Occlusion and Moyamoya Disease[J].Int J Gen Med,2022,15:699-709.DOI:10.2147/IJGM.S341015.
• [41]TASHIRO R,FUJIMURA M,NISHIZAWA T,et al.Cerebral Hyperperfusion and Concomitant Reversible Lesion at the Splenium after Direct Revascularization Surgery for Adult Moyamoya Disease:Possible Involvement of MERS and Watershed Shift Phenomenon[J].NMC Case Rep J,2021,8(1):451-456.DOI:10.2176/nmccrj.cr.2020-0337.
• [42]JEONG P S.Recognizing Moyamoya Disease in a Soldier With Recurrent Cerebrovascular Symptoms[J].Mil Med,2022:usab564.DOI:10.1093/milmed/usab564.
• [43]XU R,XIE M E,FEGHALI J,et al.Revascularization of Hemorrhagic Moyamoya Disease in a North American Cohort:The Role of Timing in Perioperative and Long-Term Outcomes[J].Neurosurgery,2022,90(4):434-440.DOI:10.1227/NEU.0000000000001850.
• [44]ZHOU Z,XU K,YU J.Endovascular treatment of main trunk aneurysms in the residual anterior circulation in moyamoya disease[J].Neuroradiol J,2022:19714009211067413.DOI:10.1177/19714009211067413.
• [45]KO H,MIN S K.Successful Treatment of Recurrent Renal Artery Stenosis in a Patient with Moyamoya Disease by AortoRenal Bypass with Autogenous Vein Graft[J].Vasc Specialist Int,2022,38:1.DOI:10.5758/vsi.210079.
• [46]UEDA Y,TANAKA Y,HARA S,et al.Differences in cerebral blood flow measurement using arterial spin labeling MRIbetween patients with moyamoya disease and patients with arteriosclerotic cerebrovascular disease[J].Acta Radiol,2022:2841851211069245.DOI:10.1177/02841851211069245.
• [47]LI Y,WANG A R,STEINBERG G K.Safety and Efficacy of Induced Hypertension and Hypervolemia in Preventing Neurologic Complications After Combined Direct and Indirect Bypass in Hemorrhagic-Onset Moyamoya Disease[J].World Neurosurg,2022,160:e381-e387.DOI:10.1016/j.wneu.2022.01.017.
• [48]LI C Q,GE Q M,SHU H Y,et al.Investigation of Altered Spontaneous Brain Activities in Patients With Moyamoya Disease Using Percent Amplitude of Fluctuation Method:AResting-State Functional MRI Study[J].Front Neurol,2021,12:801029.DOI:10.3389/fneur.2021.801029.
• [49]IJNER P,TOMPKINS G,SHIOHAMA T,et al.Structural abnormalities in paediatric moyamoya disease revealed by clinical magnetic resonance imaging,regionally distributed relative signal intensities and volumes[J].Int J Dev Neurosci,2022,82(2):146-158.DOI:10.1002/jdn.10167.
• [50]LUKSHIN V A,SHULGINA A A,USACHEV D Y,et al.Ischemic complications following surgical treatment of moyamoya disease:risk factors and prevention[J].Zh Vopr Neirokhir Im N N Burdenko,2021,85(6):26-35.DOI:10.17116/neiro20218506126.
• [51]KANOKE A,FUJIMURA M,TASHIRO R,et al.Transient Global Cerebral Hypoperfusion as a Characteristic Cerebral Hemodynamic Pattern in the Acute Stage after Combined Revascularization Surgery for Pediatric Moyamoya Disease:N-Isopropyl-P-[123I]Iodoamphetamine Single-Photon Emission Computed Tomography Study[J].Cerebrovasc Dis,2022,51(4):453-460.DOI:10.1159/000520801.